Skip to main content
Signal8
Launch Terminal

Aspen Neuroscience, Inc. (ASPE)

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Aspen Neuroscience Inc. logo

Aspen Neuroscience Inc.

NASDAQ:ASPEHealthcare
Pre-4.23%$14.26
Close$14.89AH$14.72-3.13%since
Mkt Cap$432.98M
Float17.82M
O/S29.08M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Aspen Neuroscience Inc. logoNASDAQ:ASPEPre$14.26-4.23%
About

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases.

Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD).

The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.

Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap$432.98M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateOct 30, 2026
Shares Outstanding29.08M
Float17.82M
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
0.0%
Institutional
(0)
0.1%
Insiderⓘ
(2)
0.0%
5%+ Owners
(0)
99.9%
Unattributed (incl. retail)ⓘ
Insider0.1%
Unattributed (incl. retail)99.9%
Top Shareholders
NameShares%
Hasnain Faheem profile photo
Hasnain Faheem
Executive Chair, Director
26.7K0.1%
Spaventa Andrew profile photo
Spaventa Andrew
Director
7.7K0.0%
Sources: Form 4O/S: 29.1M · checked 2 Nov 2026 · market-data provider
Insiders & Institutional Holders

Insiders

52-Week Range
Volume
Average Daily Volume1.32M
1.32M today vs 1.32M avg(-0%)

30d Avg

1.32M

60d Avg

1.32M

90d Avg

1.32M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...